Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Receivables (2016 - 2025)

Wave Life Sciences (WVE) has disclosed Receivables for 9 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables fell 10.27% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Dec 2025, down 10.27%, and an annual FY2025 reading of $1.3 million, down 10.27% over the prior year.
  • Receivables was $1.3 million for Q4 2025 at Wave Life Sciences, down from $10.0 million in the prior quarter.
  • Across five years, Receivables topped out at $60.0 million in Q1 2021 and bottomed at $1.3 million in Q4 2025.
  • Average Receivables over 4 years is $14.0 million, with a median of $7.0 million recorded in 2023.
  • The sharpest move saw Receivables tumbled 93.26% in 2024, then rose 25.35% in 2025.
  • Year by year, Receivables stood at $22.5 million in 2021, then fell by 6.28% to $21.1 million in 2023, then crashed by 93.26% to $1.4 million in 2024, then decreased by 10.27% to $1.3 million in 2025.
  • Business Quant data shows Receivables for WVE at $1.3 million in Q4 2025, $10.0 million in Q3 2025, and $1.6 million in Q2 2025.